COG

DCG Giving, a Dave Cantin Group Nonprofit, Launches Five Weeks of Giving This Holiday Season

Retrieved on: 
Tuesday, November 29, 2022
Health, Family, Consumer, Automotive, Consulting, Professional Services, Philanthropy, Oncology, Research, Children, Fund Raising, Foundation, Other Automotive, Science, Adolescence, Children's Oncology Group, Partnership, Community, DCG, Institute for Mergers, Acquisitions and Alliances, COG, MD, Child, Research, Mergers and acquisitions, Hospital, Cancer

In honor of National Day of Giving, DCG Giving , the nonprofit of the Dave Cantin Group , one of the largest financial advisory companies for mergers and acquisitions in the automotive sector, announced the launch of its Five Weeks of Giving campaign for the 2022 holiday season.

Key Points: 
  • In honor of National Day of Giving, DCG Giving , the nonprofit of the Dave Cantin Group , one of the largest financial advisory companies for mergers and acquisitions in the automotive sector, announced the launch of its Five Weeks of Giving campaign for the 2022 holiday season.
  • Making a difference in the lives of others is a keynote mission of DCG, and DCG Giving is focused on our children by providing funding specifically for pediatric cancer research and treatment, says Dave Cantin, Executive Chairman and CEO of DCG.
  • In August, DCG Giving entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.
  • Throughout this holiday season, DCG Giving will donate to the following COG institutions each at the forefront of research and clinical care, says DCG Givings Director of Philanthropy Michael Weiner, MD:
    DCG Giving is a nonprofit committed to 3 Cs: Children, Cancer, Community.

Veoci Introduces a Reinvented Continuity of Operations Planning (COOP) Solution

Retrieved on: 
Wednesday, November 9, 2022
Security, Business, Home Goods, Retail, Transport, Human Resources, Software, Consulting, Internet, Professional Services, Data Management, Logistics, Supply Chain Management, Social Media, Technology, Search Engine Optimization, Search Engine Marketing, Public Relations, Investor Relations, Communications, Small Business, Hospital, CGC, Federal, Accident, Web browser, Workforce, Communication, Education, PMP, Systems theory, Organization, NIMS, Risk, Military, Budget, Face, COG, Compliance, Operation, Daily Operation, Software as a service, Facility, Shared Awareness and Deconfliction, Life, Software, Emergency management, Business continuity planning, Continuity, Risk management, COOP

Simplifying the planning lifecycle is the goal of the Veoci COOP solution, with a key focus on making data gathering easier for operatives and stakeholders.

Key Points: 
  • Simplifying the planning lifecycle is the goal of the Veoci COOP solution, with a key focus on making data gathering easier for operatives and stakeholders.
  • Continuity of Operations Planning (COOP) is both mandatory and strategically critical for most organizations.
  • The Veoci team will be demonstrating the updated Veoci COOP solution at the 2022 IAEM conference in Savannah, Georgia, November 14th - 16th.
  • About Veoci: Veoci is a cloud-based platform for Emergency Management, Business Continuity, Continuity of Operations Planning, Team Collaboration, and Daily Operations, designed to meet the decision-making and communication requirements of multiple teams at many locations.

HYUNDAI HOPE ON WHEELS ANNOUNCES 2022 GRANT AWARD WINNERS

Retrieved on: 
Tuesday, September 27, 2022
COG, Child, Research, National Childhood Cancer Awareness Month, Social responsibility, Hope, Shazam! Power of Hope, Children's Oncology Group, Industry, Hyundai Motor America, Cancer, Paint, Hospital, Oncology, Disease, Pharmaceutical industry, Dietary supplement, Hyundai

During National Childhood Cancer Awareness Month, Hyundai Hope On Wheels to Present 75 Research and Programmatic Grants Totaling $15 Million

Key Points: 
  • During National Childhood Cancer Awareness Month, Hyundai Hope On Wheels to Present 75 Research and Programmatic Grants Totaling $15 Million
    FOUNTAIN VALLEY, Calif., Sept. 27, 2022 /PRNewswire/ --Hyundai Hope On Wheels, a 501(c)(3) nonprofit organization supported by Hyundai Motor America and its more than 820 U.S. dealers, today announced the 2022 winners of its annual research and programmatic grants totaling$15 million.
  • This year, Hyundai Hope On Wheels will present a total of 75 grants to institutions across the United States that are focused on improving outcomes and treatments for children diagnosed with cancer, including 25 Hyundai Scholar Hope Grants at$300,000each, 25 Hyundai Young Investigator Grants at$200,000each, and 25 Hyundai Impact Grants at$100,000each.
  • "We are honored to present this year's grant winners with funds to perform their lifesaving work and continue to bring hope to the brave pediatric cancer fighters and their families across the nation," saidJohn Guastaferro, executive director, Hyundai Hope On Wheels.
  • Since its inception in 1998, Hyundai Hope On Wheels has awarded more than 1,100 research grants funding critical research to help save young lives.

HYUNDAI HOPE ON WHEELS AND MEMBERS OF CONGRESS HONOR NATIONAL CHILDHOOD CANCER AWARENESS MONTH

Retrieved on: 
Thursday, September 22, 2022
Hyundai Santa Fe, COG, Child, Awareness, Childhood cancer, National Childhood Cancer Awareness Month, Hope, Organization, Children's Oncology Group, Hyundai Motor America, Cancer, Physician, Goal, Paint, Georgetown Lombardi Comprehensive Cancer Center, Research, Hospital, Congress, Multimedia, Hyundai, Legislation, Disease, Pharmaceutical industry, Toy, Heavy equipment, Wheel

"Together with Hyundai Hope On Wheels, Hyundai builds more than cars; it builds families, communities, and hope.

Key Points: 
  • "Together with Hyundai Hope On Wheels, Hyundai builds more than cars; it builds families, communities, and hope.
  • "September is National Childhood Cancer Awareness Month, a time so critical to our goals to raise awareness, drive hope, and move closer to a cure.
  • Hyundai Hope On Wheels is a 501(c)(3) nonprofit organization that is committed to finding a cure for childhood cancer.
  • Since its inception, Hyundai Hope On Wheels has pledged $200 million in support of more than 1,000 childhood cancer research grants.

Display Driver Market is expected to generate a revenue of USD 11.98 Billion by 2030, Globally, at 4.71% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, September 14, 2022
Small Device C Compiler, Adoption, COG, Tablet, Electronics, Samsung Electronics, Synaptics, Research, LCD, Rohm, Smartphone, Market research, Growth, Industry, Television, MediaTek, USD, Internet, OLED, Display driver, Somatosensory system, Silicon, COF, CAGR, Mobile phone, Geography

JERSEY CITY, New Jersey, Sept. 14, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Display Driver Market" By Driver Type (Display Driver IC (DDIC), and Touch and Display Driver Integration (TDDI)), By Devices (Small Devices, Medium-Sized and Large Devices, Smart Wearables, and Others), By Package Type (Chip-On-Glass (COG), and Chip-On-Film (COF)), By Display Technology (LCD, OLED, and Others), and By Geography.

Key Points: 
  • According to an extensive study conducted by Verified Industry Research on the Display Driver Market, the market was valued at USD 7.93 Billion in 2021 and is projected to reach USD 11.98 Billion by 2030, growing at a CAGR of 4.71% from 2022 to 2030.
  • Even when the user's video card isn't being used to its full capabilities, the computer may still utilize it thanks to a display driver.
  • The screens would even have a significantly reduced resolution than usual if the proper display driver wasn't installed, which would slow down games.
  • Verified Market Research has segmented the Global Display Drivers Market into Driver Type, Devices, Package Type, Display Technology, and on the basis of Geography.

Display Driver Market is expected to generate a revenue of USD 11.98 Billion by 2030, Globally, at 4.71% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, September 14, 2022
Small Device C Compiler, Adoption, COG, Tablet, Electronics, Samsung Electronics, Synaptics, Research, LCD, Rohm, Smartphone, Market research, Growth, Industry, Television, MediaTek, USD, Internet, OLED, Display driver, Somatosensory system, Silicon, COF, CAGR, Mobile phone, Geography

JERSEY CITY, New Jersey, Sept. 14, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Display Driver Market" By Driver Type (Display Driver IC (DDIC), and Touch and Display Driver Integration (TDDI)), By Devices (Small Devices, Medium-Sized and Large Devices, Smart Wearables, and Others), By Package Type (Chip-On-Glass (COG), and Chip-On-Film (COF)), By Display Technology (LCD, OLED, and Others), and By Geography.

Key Points: 
  • According to an extensive study conducted by Verified Industry Research on the Display Driver Market, the market was valued at USD 7.93 Billion in 2021 and is projected to reach USD 11.98 Billion by 2030, growing at a CAGR of 4.71% from 2022 to 2030.
  • Even when the user's video card isn't being used to its full capabilities, the computer may still utilize it thanks to a display driver.
  • The screens would even have a significantly reduced resolution than usual if the proper display driver wasn't installed, which would slow down games.
  • Verified Market Research has segmented the Global Display Drivers Market into Driver Type, Devices, Package Type, Display Technology, and on the basis of Geography.

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

Retrieved on: 
Monday, August 22, 2022
COVID-19, International investment agreement, Human, Science, Securities Act of 1933, Food and Drug Administration, Germ cell tumor, Drug Quality and Security Act, Cisplatin, U.S. Securities and Exchange Commission, Hepatoblastoma, GLOBE, Company, Risk, Potential, Patient, Medulloblastoma, EMA, Survival, Contagious disease, Sale, Incidence, RESEARCH, Food, SEC, Instability, Bridge bank, FDA, Platinum, CRL, Hearing loss, COG, Cancer, Ototoxicity, FENC, Security (finance), NDA, Sumathi Best Television Current Reporting Award, NASDAQ, Survivor, PDUFA, MAA, Literacy, Investment, Patent, PARK, Disease, Osteosarcoma, STS, Coronavirus, Fennec, OHSU, Health, TSX, Goal, Neuroblastoma, Kool-Aid, Failure, Annual report, Forward-looking statement, Pharmaceutical industry, Nasdaq, Petrichor, Access

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management. Under the terms of the investment agreement, an additional $20 million is to be funded upon the potential U.S. Food and Drug Administration (FDA) approval of PEDMARKTM by September 30, 2022 and satisfaction of other closing conditions. Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.

Key Points: 
  • Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKfor the prevention of platinum-induced ototoxicity in pediatric patients.
  • The Petrichor has completed over 90 investments representing more than$5 billionin invested capital and has held over 30 board seats.
  • If the FDA does not approve the NDA resubmission of PEDMARK, we will not have access to the Petrichor financing.

Biden's Carbon Emissions Bill Misses Big, Commercial Windows Not Addressed

Retrieved on: 
Monday, August 15, 2022
NFRC, Public health, Glass, Electricity, University College London, Federation, Carbon, Industry, R-2, Technology, Policy, White House, ZeroNet, Patent, Research, Energy Institute, Engineering, Insulator (electricity), CO2, COG, HVAC, Lighting, Foot, Steel, ST, Climate, Environmental policy of the Joe Biden administration, Recycling, Heating, ventilation, and air conditioning, Construction, Renewable energy, Coal

ST. MERRILL, Wis., Aug. 15, 2022  /PRNewswire-PRWeb/ --  The Biden Administration recently introduced the Climate Smart Buildings Initiative. Unfortunately, these efforts will have limited benefits without addressing commercial windows and curtain walls. The bill proposes systematically modernizing public buildings by "increasing on-site clean electricity generation, adding the latest clean energy technology… installing efficient lighting and insulation, and installing and integrating electric vehicle supply equipment."(1) "Commercial building systems like lighting and HVAC are routinely updated and replaced, but windows and curtain walls are expected to last for up to 50 to 100 years without replacement," says Todd Frederick, Founder and President of FreMarq Innovations, who after 40 years of being in the industry develop the most economic and energy efficient curtain wall and window system for commercial building in the market today.

Key Points: 
  • FreMarq Innovations manufacturing firm says bill misses the single most critical element in a net-zero economy: commercial windows and curtain walls.
  • Unfortunately, these efforts will have limited benefits without addressing commercial windows and curtain walls.
  • If we are really going to hit our carbon emission reduction targets this needs to be addressed today. "
  • As a result, total carbon emissions from gas and electricity from high-rise buildings are twice as high as in low-rise."

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 12, 2022
FDA, PDUFA, Cisplatin, Literacy, Survival, Contagious disease, Risk, NDA, Cancer, Forward-looking statement, OHSU, Hepatoblastoma, Neuroblastoma, Failure, European Medicines Agency, Oregon Health & Science University, CRL, Incidence, Patent, Security (finance), Annual report, Patient, Instability, COVID-19, Company, MAA, Medulloblastoma, U.S. Securities and Exchange Commission, COG, Coronavirus, Exchange, Fennec, Survivor, Hearing loss, Ototoxicity, Petrichor, Disease, Goal, Platinum, Osteosarcoma, Human, Kool-Aid, Germ cell tumor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, STS, Food, EMA, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the fiscal quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients.
  • Fennec disclaims any obligation to update these forward-looking statements except as required by law.
  • For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

DCG Giving, a Dave Cantin Group Nonprofit, Partners with Children’s Oncology Group to Fight Pediatric Cancer and Support Cutting-Edge Research and Treatment

Retrieved on: 
Wednesday, August 10, 2022
Finance, Consulting, Professional Services, Philanthropy, Other Health, Health, Foundation, Other Philanthropy, Oncology, Other Professional Services, Children's Oncology Group, Hospital, Organic, Children's Hospital Los Angeles, Mergers and acquisitions, St. Jude Children's Research Hospital, Industry, Children's Hospital of Philadelphia, Adolescence, Memorial Sloan Kettering Cancer Center, Research, Organization, DCG, Cincinnati Children's Hospital Medical Center, Patient, Institute for Mergers, Acquisitions and Alliances, Center, Foundation, COG, Johns Hopkins Children's Center, Partnership, Community, Geisinger Medical Center, American Cancer Society, Dana–Farber Cancer Institute, Philadelphia, Seattle Children's, Mobile phone, Birth control, MD, Cancer, Child

Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.

Key Points: 
  • Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.
  • The goal of DCG Giving is to offer financial and structural support to COGs local child and adolescent cancer programs and assist patients and their families across the country.
  • We are proud to partner with COG, which is trailblazing the advancement for childhood and adolescent cancer research and treatment, said Executive Director Michael Weiner, MD.
  • The organizations mission is to fund lifesaving child and adolescent cancer research and treatment in communities nationwide.